Q-omics provides the consensus-scored ABRA profile across patient tissues and cancer cell-line models. ABRA expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, ABRA is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, ABRA RNA expression shows 12,722 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight DLBC, HNSC, and KIRP as cancer lineages where ABRA shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ABRA — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ABRA survival associations across molecular data types. ABRA RNA expression shows survival associations in the most cancer types (20), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ABRA RNA expression–survival associations across cancer types. High ABRA expression shows unfavorable associations in DLBC, UVM, ESCA and HNSC, but favorable associations in BLCA and LUAD. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify DLBC as the clearest survival context for ABRA RNA expression.
This table summarizes ABRA tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for ABRA. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ABRA shows lower tumor expression in HNSC, BLCA, LUSC, UCEC, KICH and LUAD. The HNSC box plot shows higher ABRA RNA expression in normal versus tumor tissue (log2 FC = −1.614, t-test p < 0.001).
This table shows molecular features associated with ABRA in patient tissues and cancer cell lines. In patient samples, ABRA shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, ABRA RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and KIDNEY.
